Abeler VM, Royne O, Thoresen S et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355–364.
Wang WL, Soslow R, Hensley M et al. Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases. Am J Surg Pathol 2011;35:522–529.
Mayerhofer K, Obermair A, Windbichler G et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999;74:196–201.
Lim D, Wang WL, Lee CH et al. Old versus new FIGO staging systems in predicting overall survival in patients with uterine leiomyosarcoma: a study of 86 cases. Gynecol Oncol 2013;128:322–326.
Raut CP, Nucci MR, Wang Q et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer 2009;45:2818–2824.
Edge SB. American Joint Committee on Cancer AJCC Cancer Staging Manual. Springer: New York, USA, 2010;648 p.
Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009;104:177–178.
Zivanovic O, Jacks LM, Iasonos A et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer 2012;118:660–669.
Zivanovic O, Leitao MM, Iasonos A et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol 2009;27:2066–2072.
Iasonos A, Keung EZ, Zivanovic O et al. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer 2013;119:1816–1822.
Chiang S, Oliva E. Recent developments in uterine mesenchymal neoplasms. Histopathology 2013;62:124–137.
Oliva E, Carcangiu ML, Carinelli S et al. Mesenchymal tumours In: Kurman RJ, Carcangiu ML, Herrington CS et al (eds). WHO Classification of Tumours of Female Reproductive Organs. IARC Press: Lyons, France, 2014, p 135–147.
Burch DM, Tavassoli FA. Myxoid leiomyosarcoma of the uterus. Histopathology 2011;59:1144–1155.
Kindelberger D, Hollowell M, Otis C et al. A clinicopathologic study of ten cases. Mod Pathol 2007;20:203A–204A.
King ME, Dickersin GR, Scully RE. Myxoid leiomyosarcoma of the uterus. A report of six cases. Am J Surg Pathol 1982;6:589–598.
Kurman RJ, Norris HJ. Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma: a clinical and pathologic analysis of 26 cases. Cancer 1976;37:1853–1865.
Prayson RA, Goldblum JR, Hart WR. Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients. Am J Surg Pathol 1997;21:383–391.
Toledo G, Oliva E. Smooth muscle tumors of the uterus: a practical approach. Arch Pathol Lab Med 2008;132:595–605.
Toon C, McGahan S, Henderson P et al. Myxoid symplastic leiomyoma of the uterus. Pathology 2006;38:275–277.
Salm R, Evans DJ. Myxoid leiomyosarcoma. Histopathology 1985;9:159–169.
Veras E, Malpica A, Deavers MT et al. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol 2009;28:316–321.
Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994;18:535–558.
Giuntoli RL 2nd, Metzinger DS, DiMarco CS et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460–469.
Akhan SE, Yavuz E, Tecer A et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol 2005;99:36–42.
Pautier P, Genestie C, Rey A et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000;88:1425–1431.
Veras E, Zivanovic O, Jacks L et al. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. Am J Surg Pathol 2011;35:1626–1637.
Lim D, Alvarez T, Nucci MR et al. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol 2013;37:650–658.
Wang W, Soslow RA, Zannoni G, al e. The utility of tumor cell necrosis in the diagnosis of primary leiomyosarcoma of the uterus: An analysis of 77 cases. Mod Pathol 2006;18:201A.
Croce S, Young RH, Oliva E. Uterine leiomyomas with bizarre nuclei: a clinicopathologic study of 59 cases. Am J Surg Pathol 2014;38:1330–1339.
Downes KA, Hart WR. Bizarre leiomyomas of the uterus: a comprehensive pathologic study of 24 cases with long-term follow-up. Am J Surg Pathol 1997;21:1261–1270.
Mills AM, Ly A, Balzer BL et al. Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up. Am J Surg Pathol 2013;37:634–642.
Mittal KR, Chen F, Wei JJ et al. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas. Mod Pathol 2009;22:1303–1311.
Bodner-Adler B, Bodner K, Czerwenka K et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol 2005;96:62–66.
Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol 2008;27:326–332.
Gannon BR, Manduch M, Childs TJ. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants. Int J Gynecol Pathol 2008;27:68–73.
Hakverdi S, Gungoren A, Yaldiz M et al. Immunohistochemical analysis of p16 expression in uterine smooth muscle tumors. Eur J Gynaecol Oncol 2011;32:513–515.
D'Angelo E, Espinosa I, Ali R et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol 2011;121:328–333.
O'Neill CJ, McBride HA, Connolly LE et al. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 2007;50:851–858.
Sung CO, Ahn G, Song SY et al. Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors. Int J Gynecol Pathol 2009;28:529–534.
Croce S, Chibon F. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives. Eur J Cancer 2015;51:1603–1610.
Je EM, Kim MR, Min KO et al. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer 2012;131:E1044–E1047.
McGuire MM, Yatsenko A, Hoffner L et al. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 2012;7:e33251.
Perot G, Croce S, Ribeiro A et al. MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 2012;7:e40015.
Bertsch E, Qiang W, Zhang Q et al. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol 2014;27:1144–1153.
Matsubara A, Sekine S, Yoshida M et al. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Histopathology 2013;62:657–661.
Schwetye KE, Pfeifer JD, Duncavage EJ. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol 2014;45:65–70.
Reyes C, Karamurzin Y, Frizzell N et al. Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry. Mod Pathol 2014;27:1020–1027.
Bennett J, Chiang S, Chen YB et al. Leiomyoma with Bizarre Nuclei: Correlation Between Morphology and Fumarate Hydratase/S-(2-Succino)-Cysteine Expression. Mod Pathol 2015;28:276a.
Sanz-Ortega J, Vocke C, Stratton P et al. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol 2013;37:74–80.
Garg K, Tickoo SK, Soslow RA et al. Morphologic features of uterine leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome: a case report. Am J Surg Pathol 2011;35:1235–1237.
Alsolami S, El-Bahrawy M, Kalloger SE et al. Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas. Int J Gynecol Pathol 2014;33:560–567.
O'Connor DM, Norris HJ. Mitotically active leiomyomas of the uterus. Hum Pathol 1990;21:223–227.
Prayson RA, Hart WR. Mitotically active leiomyomas of the uterus. Am J Clin Pathol 1992;97:14–20.
Myles JL, Hart WR. Apoplectic leiomyomas of the uterus. A clinicopathologic study of five distinctive hemorrhagic leiomyomas associated with oral contraceptive usage. Am J Surg Pathol 1985;9:798–805.
Ip PP, Lim D, Cheung AN et al. Immunoexpression of p16 in Uterine Leiomyomas with Infarct Type Necrosis. Mod Pathol 2015;28:291 A.
Oliva E, Young RH, Clement PB et al. Cellular benign mesenchymal tumors of the uterus. A comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and six endometrial stromal nodules, two frequently confused tumors. Am J Surg Pathol 1995;19:757–768.
Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology 2007;39:55–71.
Chen E, O'Connell F, Fletcher CD. Dedifferentiated leiomyosarcoma: clinicopathological analysis of 18 cases. Histopathology 2011;59:1135–1143.
McCluggage WG, Lioe TF, McClelland HR et al. Rhabdomyosarcoma of the uterus: report of two cases, including one of the spindle cell variant. Int J Gynecol Cancer 2002;12:128–132.
Baker P, Oliva E. Intraoperative Consultation during Gynecologic Pathology (Vagina, Vuolva, Uterine Cervix, and Corpus). In: Marchevsky AM, Abdul Karim FW, Balzer BL editors. Intraoperative Consultation. Elsevier Saunders: Philadelphia, PA, USA, 2015, p 292–309.
Clement PB, Young RH, Scully RE. Diffuse, perinodular, and other patterns of hydropic degeneration within and adjacent to uterine leiomyomas. Problems in differential diagnosis. Am J Surg Pathol 1992;16:26–32.
Chesnais AL, Watkin E, Beurton D et al. Myxoid mesenchymal tumors of uterus: endometrial stromal and smooth muscle tumors, myxoid variant. Ann Pathol 2011;31:152–158.
Norris HJ, Hilliard GD, Irey NS. Hemorrhagic cellular leiomyomas ("apoplectic leiomyoma") of the uterus associated with pregnancy and oral contraceptives. Int J Gynecol Pathol 1988;7:212–224.
Clement PB, Young RH, Scully RE. Intravenous leiomyomatosis of the uterus. A clinicopathological analysis of 16 cases with unusual histologic features. Am J Surg Pathol 1988;12:932–945.
Ip PP, Tse KY, Tam KF. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol 2010;17:91–112.
Oliva E, Young RH, Clement PB et al. Myxoid and fibrous endometrial stromal tumors of the uterus: a report of 10 cases. Int J Gynecol Pathol 1999;18:310–319.
Yilmaz A, Rush DS, Soslow RA. Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation. Am J Surg Pathol 2002;26:1142–1150.
Oliva E. Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations. Int J Gynecol Pathol 2014;33:374–384.
Lee CH, Marino-Enriquez A, Ou W et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: A histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012;36:641–653.
Baker P, Oliva E. Endometrial stromal tumours of the uterus: a practical approach using conventional morphology and ancillary techniques. J Clin Pathol 2007;60:235–243.
Nucci MR, O'Connell JT, Huettner PC et al. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol 2001;25:455–463.
Lee CH, Ali RH, Rouzbahman M et al. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol 2012;36:1562–1570.
Leitao MM, Soslow RA, Nonaka D et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004;101:1455–1462.
Loddenkemper C, Mechsner S, Foss HD et al. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma. Am J Surg Pathol 2003;27:1458–1462.
Oliva E, Young RH, Amin MB et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002;26:403–412.
Leitao MM Jr, Hensley ML, Barakat RR et al. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol 2012;124:558–562.
Bodner K, Bodner-Adler B, Kimberger O et al. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res 2003;23:729–732.
Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001;32:984–987.
Gilks CB, Taylor GP, Clement PB. Inflammatory pseudotumor of the uterus. Int J Gynecol Pathol 1987;6:275–286.
Parra-Herran C, Quick CM, Howitt BE et al. Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course. Am J Surg Pathol 2015;39:157–168.
Rabban JT, Zaloudek CJ, Shekitka KM et al. Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Am J Surg Pathol 2005;29:1348–1355.
Veras E, Junkins-Hopkins JM, Marinis S et al. Myometrial myxoidosis: a report of 2 cases of a distinctive type of secondary myometrial hypertrophy in patients with lupus erythematosus. Int J Gynecol Pathol 2009;28:164–171.
Pugh A, McCluggage WG, Hirschowitz L. Multifocal uterine myxoid change: a newly recognized association with neurofibromatosis type 1. Int J Gynecol Pathol 2012;31:580–583.
Raspollini MR, Pinzani P, Simi L et al. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT. Gynecol Oncol 2005;98:334–335.
Rushing RS, Shajahan S, Chendil D et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol 2003;91:9–14.
Novelli M, Rossi S, Rodriguez-Justo M et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010;57:259–270.
Fadare O. Perivascular epithelioid cell tumor (PEComa) of the uterus: an outcome-based clinicopathologic analysis of 41 reported cases. Adv Anat Pathol 2008;15:63–75.
Folpe AL, Mentzel T, Lehr HA et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 2005;29:1558–1575.
Schoolmeester JK, Howitt BE, Hirsch MS et al. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases. Am J Surg Pathol 2014;38:176–188.
Vang R, Kempson RL. Perivascular epithelioid cell tumor ('PEComa') of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Am J Surg Pathol 2002;26:1–13.
Conlon N, Soslow RA, Murali R. Perivascular epithelioid tumours (PEComas) of the gynaecological tract. J Clin Pathol 2015;68:418–426.
Rao Q, Cheng L, Xia QY et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology 2013;62:642–650.
Iwata J, Fletcher CD. Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: a systematic study of 100 cases. Pathol Int 2000;50:7–14.
Silva EG, Deavers MT, Bodurka DC et al. Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa. Am J Surg Pathol 2004;28:244–249.
Fisher C. The value of electronmicroscopy and immunohistochemistry in the diagnosis of soft tissue sarcomas: a study of 200 cases. Histopathology 1990;16:441–454.
Agaram NP, Sung YS, Zhang L et al. Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. Am J Surg Pathol 2015;39:813–825.
Schoolmeester JK, Dao LN, Sukov WR et al. TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol 2015;39:394–404.
Laury AR, Perets R, Piao H et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011;35:816–826.
Fadare O, Zhao C, Khabele D et al. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours. Pathology 2015;47:105–111.
Iwamoto M, Nakatani Y, Fugo K et al. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. Hum Pathol 2015;46:957–962.
Lim D, Ip PP, Cheung AN et al. Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma. Am J Surg Pathol 2015;39:1061–1069.
Anderson SE, Nonaka D, Chuai S et al. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gynecol Cancer 2006;16:849–853.
Blom R, Guerrieri C, Stal O et al. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998;68:54–61.
Leiser AL, Anderson SE, Nonaka D et al. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol 2006;101:86–91.
Clement PB, Scully RE. Uterine tumors resembling ovarian sex-cord tumors. A clinicopathologic analysis of fourteen cases. Am J Clin Pathol 1976;66:512–525.
Czernobilsky B. Uterine tumors resembling ovarian sex cord tumors: an update. Int J Gynecol Pathol 2008;27:229–235.
de Leval L, Lim GS, Waltregny D et al. Diverse phenotypic profile of uterine tumors resembling ovarian sex cord tumors: an immunohistochemical study of 12 cases. Am J Surg Pathol 2010;34:1749–1761.
Hurrell DP, McCluggage WG. Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers. J Clin Pathol 2007;60:1148–1154.
Irving JA, Carinelli S, Prat J. Uterine tumors resembling ovarian sex cord tumors are polyphenotypic neoplasms with true sex cord differentiation. Mod Pathol 2006;19:17–24.
Krishnamurthy S, Jungbluth AA, Busam KJ et al. Uterine tumors resembling ovarian sex-cord tumors have an immunophenotype consistent with true sex-cord differentiation. Am J Surg Pathol 1998;22:1078–1082.
Chiang S, Staats PN, Senz J et al. FOXL2 mutation is absent in uterine tumors resembling ovarian sex cord tumors. Am J Surg Pathol 2015;39:618–623.
Chew I, Post MD, Carinelli SG et al. p16 expression in squamous and trophoblastic lesions of the upper female genital tract. Int J Gynecol Pathol 2010;29:513–522.
Mao TL, Seidman JD, Kurman RJ et al. and p16 immunoreactivity in epithelioid trophoblastic tumor—an aid in differential diagnosis. Am J Surg Pathol 2006;30:1105–1110.
Ordi J, Romagosa C, Tavassoli FA et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol 2003;27:178–186.
Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol 2001;20:31–47.
Young RH, Kurman RJ, Scully RE. Proliferations and tumors of intermediate trophoblast of the placental site. Semin Diagn Pathol 1988;5:223–237.
Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol 1998;22:1393–1403.
Shih IM, Kurman RJ. p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am J Surg Pathol 2004;28:1177–1183.
Kalhor N, Ramirez PT, Deavers MT et al. Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol 2009;33:633–638.
Kurman RJ, Young RH, Norris HJ et al. Immunocytochemical localization of placental lactogen and chorionic gonadotropin in the normal placenta and trophoblastic tumors, with emphasis on intermediate trophoblast and the placental site trophoblastic tumor. Int J Gynecol Pathol 1984;3:101–121.
Shih IM, Kurman RJ. Immunohistochemical localization of inhibin-alpha in the placenta and gestational trophoblastic lesions. Int J Gynecol Pathol 1999;18:144–150.
Nielsen GP, Oliva E, Young RH et al. Alveolar soft-part sarcoma of the female genital tract: a report of nine cases and review of the literature. Int J Gynecol Pathol 1995;14:283–292.
Roma AA, Yang B, Senior ME et al. TFE3 immunoreactivity in alveolar soft part sarcoma of the uterine cervix: case report. Int J Gynecol Pathol 2005;24:131–135.
Oliva E, Clement PB, Young RH. Epithelioid endometrial and endometrioid stromal tumors: a report of four cases emphasizing their distinction from epithelioid smooth muscle tumors and other oxyphilic uterine and extrauterine tumors. Int J Gynecol Pathol 2002;21:48–55.